Posted by Michael Wonder on 22 Feb 2022
Immunotherapy Keytruda gets insurance benefits
22 February 2022 - MSD’s anti-PD-1 immunotherapy Keytruda (pembrolizumab) obtained health insurance benefits five years after winning marketing approval to treat advanced non-small cell lung cancer in Korea in March 2017.
The Government also established the reimbursement criteria for Xospata (gilteritinib), the first targeted therapy for FLT3 mutation-positive patients with relapsed/refractory acute myeloid leukaemia with poor prognosis and no targeted treatment options.
